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ABSTRACT
Introduction: Biologic therapies are used to
treat several inflammatory diseases, including
rheumatoid arthritis (RA), psoriasis (PsO),
psoriatic arthritis (PsA), and ankylosing
spondylitis (AS). Data from a commercial
claims database were used to evaluate
utilization and cost of biologic treatment for
these conditions.
Methods: Data were obtained from the Optum
Research Database. Patients were aged
18–63 years with diagnosis of moderate to
severe RA, PsO, PsA, and/or AS and first
(index) claim for biologics abatacept,
adalimumab, certolizumab pegol, etanercept,
golimumab, infliximab, rituximab,
tocilizumab, or ustekinumab or non-biologic
tofacitinib between March 1, 2011 and February
28, 2013. One-year treatment costs were based
on observed paid amounts and used to impute
dosing. Treatment patterns (persistence,
switching, discontinuing, restarting) were
evaluated.
Results: Data from 20,159 patients were
analyzed for index medications abatacept
(n = 583), adalimumab (n = 6521),
certolizumab pegol (n = 415), etanercept
(n = 9116), golimumab (n = 231), infliximab
(n = 1906), rituximab (n = 295), tocilizumab
(n = 165), ustekinumab (n = 922), and
tofacitinib (n = 5). For patients with RA only,
costs were lowest for tofacitinib ($18,769),
rituximab ($19,569), or abatacept ($21,877),
and ranged from $23,682 to $30,269 for all
other medications. For patients with PsO only,
costs were lowest for adalimumab ($29,186),
etanercept ($31,212), and infliximab ($32,409)
compared with ustekinumab ($53,746). For
patients with PsA only, costs were lowest for
etanercept ($26,916), followed by golimumab
($27,987), adalimumab ($28,749), and
infliximab ($31,974). Costs were lowest with
etanercept for RA plus PsA ($25,477) and for
PsO plus PsA ($29,376), and with golimumab
for AS only ($24,225). Across indications,
annual costs were $29,521, $27,488, and
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$28,672 for adalimumab, etanercept, and
infliximab, respectively; persistence was
greatest with infliximab (range 66–79%)
compared with 11–59% for all other biologics.
Conclusion: One-year treatment costs varied
considerably between medications and
indications. Some newly approved agents had
lower costs but further research is needed to
confirm these estimates as more patients are
treated.
Funding: Immunex (a wholly owned subsidiary
of Amgen Inc.) and Wyeth (acquired by Pfizer).
Keywords: Ankylosing spondylitis; Biologics;
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INTRODUCTION
Many inflammatory conditions are severe,
chronic, and disabling diseases that can
manifest in joints and skin. Rheumatoid
arthritis (RA), which affects approximately
1.5 million adults in the US and an
estimated 0.5–1% of people in developed
nations, primarily affects the synovial
membrane in the joints [1]. Psoriasis (PsO) is
a skin disease occurring in approximately 4.5
million adults in the US, with an estimated
prevalence of 1.4–2.5% in children,
adolescents, and adults in the US [2]. PsO is
frequently accompanied by comorbid psoriatic
arthritis (PsA), a disfiguring form of arthritis
with an estimated prevalence of 11% in
patients with PsO in the US [3]. Ankylosing
spondylitis (AS), with prevalence estimated to
be 30–900 per 100,000 people in the US, is a
type of arthritis that affects the spine [1]. In
addition to symptoms associated with these
diseases (pain and swelling of joints and
plaque formation on skin), patients suffer
impaired health-related quality of life [4, 5].
Biologic therapies that target specific
components of the immune system are
important for treatment of autoimmune
diseases. These include agents that target
tumor necrosis factor (adalimumab,
certolizumab pegol, etanercept, golimumab,
and infliximab), interleukin (IL)-6 receptor
(tocilizumab), CD20 (rituximab), IL-12 and
IL-23 (ustekinumab), and T cell stimulators
(abatacept). A recently approved non-biologic
therapy that targets JAK (tofacitinib) is also used
to treat RA; this medication has a similar
chemical profile, price, and target population
in the product label relative to the biologics,
and is therefore included in this analysis. These
drugs differ in mode of administration, dosing
level, dosing schedule, and whether they are
approved for first-line use after non-biologic
disease-modifying antirheumatic drug
(DMARD) failure. Adalimumab, certolizumab
pegol, etanercept, golimumab, and
ustekinumab are administered as subcutaneous
(SC) injections; infliximab and rituximab are
administered as intravenous (IV) infusions; and
tofacitinib is administered orally (PO).
Abatacept, tocilizumab, and golimumab are
available for both SC and IV administration.
The cost of biologic therapies is high
compared to non-biologic DMARDs;
evidence-based assessment of comparative
costs between biologics is critical to ensure
rational healthcare resource allocation. Data
comparing costs across indications from the
payer’s perspective and an understanding of
biologic dosing patterns across different
populations and payers are critical for
formulary decision-makers to develop
evidence-based formularies. Although prior
studies evaluated the comparative costs of
biologics across multi-payer claims databases,
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the data used in those studies are now relatively
outdated and such analyses of multi-payer data
may be less applicable to specific payers. We
now report the results from a biologic
utilization model using more recent utilization
data from claims for beneficiaries on a biologic




Data for this study were obtained from the
Optum Research Database, which contains
medical and pharmacy claims data with linked
enrollment information. For 2011, data for
approximately 12.8 million individuals are
available. The enrollees in the database are
widely distributed across the US. This article
does not contain any new studies with human or
animal subjects performed by any of the authors.
Study Design
The identification period for eligible patients
was from March 1, 2011 through February 28,
2013. The index date for each patient was the
date of the first claim for the index biologic.
Index medications included the biologics
abatacept (administered IV), adalimumab (SC),
certolizumab pegol (SC), etanercept (SC),
golimumab (SC), infliximab (IV), rituximab
(IV), tocilizumab (IV), and ustekinumab (SC),
and the non-biologic tofacitinib (PO). The
baseline period was the 180 days before the
index date and the follow-up period was the
360 days starting on the index date. Patients
were considered persistent if they did not
switch from their index biologic or have a gap
in therapy of at least 45 days at any time during
the 1-year follow-up. Patients who were not
persistent were further classified as switching,
restarting, or discontinuing without switching
or restarting.
Patients
To be eligible for inclusion in the study, patients
had to: have a diagnosis of RA (International
Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] code
714.0x), PsO (ICD-9-CM code 696.1), PsA
(ICD-9-CM code 696.0), and/or AS (ICD-9-CM
code 720.0); have a fill or infusion for an index
biologic during the identification period that
was US Food and Drug
Administration-approved for the diagnosed
condition; have continuous enrollment during
the baseline period through the follow-up
period; have valid demographic information;
be 18–63 years of age on index date; and have
valid cost values (paid amount on claim[$0)
during the baseline and follow-up periods.
Exclusion criteria included: a claim for [1
biologic of interest on the index date;
diagnosis of juvenile idiopathic arthritis,
Crohn’s disease, ulcerative colitis,
non-Hodgkin’s lymphoma, or chronic
lymphocytic leukemia during the 180 days
prior to or on index date (other indications for
these biologics); have a medical claim for
SC-administered biologic or have a pharmacy
claim for IV-administered biologic; receipt of a
dose of a biologic that exceeded twice the
approved maximum weekly dose; or receipt of
SC abatacept or a medical claim for
ustekinumab. Patients were assigned to study
cohorts based on index medication and
treatment indication. Patients were categorized
as new to biologic therapy (no claim for biologic
during the baseline period) or continuing on
index biologic therapy (C1 claim during the
baseline period).
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Study Measures
Demographic characteristics, biologic dose, and
treatment patterns were collected. The total
costs of each biologic during the 1-year
follow-up period were calculated by
considering the total dose of the index
biologic while the patient was persistent, the
total dose of all biologics after the patients
switched/restarted biologic therapy (for patients
who were not persistent) and the total number
of administrations. The total dose of each
biologic was examined after persistence
through the remainder of the follow-up
period, including the dose of index biologic
for patients who restarted therapy. For each
claim, the dose (mg) was calculated based on
the observed paid amount using the following
formula: claim dose = (paid amount on claim)/
(cost per unit) 9 (strength associated with unit
price). Wholesale acquisition costs (WAC) as of
January 1, 2015 were imputed to the total index
and non-index biologic doses, while 2015
Medicare schedule fees were assigned to
biologic administration units to generate
biologic and related administration costs,
respectively. Injection/infusion administration
fees were based on the 2015 Medicare Physician
Fee Schedule.
Statistical Considerations
Frequency and percentage were calculated for
categorical patient characteristics and study
outcomes, including treatment patterns.
Analyses were conducted using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA). The mean
annual costs per treated patient were estimated
by dividing the calculated total cost incurred by
all patients treated with the biologic at index
within each disease subcohort. No adjusted
analyses were conducted, as the findings
were meant to provide population-wide
estimates for eligible patients included in this




A total of 59,436 patients were treated with an
eligible biologic during the identification period
and of these, 20,159 met all of the inclusion/
exclusion criteria (Fig. 1). The most commonly
used index medications were etanercept (45%),
adalimumab (32%), and infliximab (9%;
Table 1). The most common indications were
RA only (47%), PsO only (25%), and PsA only
(9%). The mean age of the population was
47.6 years; mean age was\45 years for patients
treated with ustekinumab and [50 years for
patients treated with abatacept, tocilizumab,
and rituximab. The majority (55–84%) of
patients were female except for patients
treated with ustekinumab (46% female).
Patients treated with abatacept, adalimumab,
etanercept, golimumab, infliximab,
tocilizumab, and ustekinumab were most
likely to have continued therapy from baseline
through follow-up, and patients treated with
certolizumab or rituximab were most likely to
be new to their index therapy. All patients on
tofacitinib were new to their index therapy
(demographics/clinical characteristics at
baseline not shown because of small sample
size).
Cost Per Treated Patient
When examining costs among patients with RA
only, costs were lowest for those treated with
tofacitinib ($18,769; n = 5), rituximab ($19,569;
n = 295), or abatacept ($21,877; n = 583),
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whereas patients treated with tocilizumab,
etanercept, certolizumab, infliximab,
golimumab, and adalimumab had average
costs ranging from $23,682 to $30,269
(n range = 165–9116) (Table 2). Among
patients diagnosed with PsO only, those
Fig. 1 Patient attrition. CD Crohn’s disease, CLL chronic lymphocytic leukemia, IV intravenous, JIA juvenile idiopathic
arthritis, NHL non-Hodgkin’s lymphoma, SC subcutaneous, UC ulcerative colitis
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treated with ustekinumab had the greatest
average annual biologic costs ($53,746;
n = 922) compared to adalimumab ($29,186;
n = 6521), etanercept ($31,212; n = 9116), and
infliximab ($32,409; n = 1906). For patients
diagnosed with PsA only, costs were lowest
among those treated with etanercept ($26,916;
n = 231) followed by golimumab ($27,987;
n = 9116), adalimumab ($28,749; n = 6521),
and infliximab ($31,974; n = 1906).
Three medications (adalimumab, etanercept,
and infliximab) were approved for the
treatment of all four conditions. Across
indications, annual costs were $29,521,
$27,488, and $28,672 for adalimumab,
etanercept, and infliximab, respectively.
Within those 3 medication cohorts costs
ranged from $25,131 to $31,212 for
etanercept, $28,129 to $30,269 for
adalimumab, and $26,370 to $34,541 for
infliximab. For etanercept and infliximab,
costs were greatest among patients with PsO
only or PsO/PsA, whereas patients treated with
adalimumab had the greatest costs among those
diagnosed with RA only. Within each of the
indications, except PsO only, the lowest cost
was observed among patients treated with
etanercept; for patients with PsO only, the
lowest cost was observed among patients
treated with adalimumab.
Treatment Patterns
Across all patients, persistence was greatest
among patients treated with infliximab
(66–79%) compared to 41–59% for all other
medications except golimumab and tofacitinib
(Table 3). Patients treated with golimumab had
persistence rates of 11–25% due in large part to
higher rates of switching (50–76%). Persistence
rates were generally 15–25% higher among
patients continuing on their index therapy
compared to those who were new to therapy.
DISCUSSION
This was a retrospective analysis of total annual
cost of biologic treatment and biologic
utilization among patients diagnosed with at
least one of four autoimmune conditions: RA,
PsO, PsA, or AS. The most commonly used
medications were etanercept, adalimumab, and
infliximab, which is consistent with previous
findings [6–8]. Notably, the most common
medications had been approved longer than
the other biologics included in the study. While
most of the patients were considered to be
continuing on existing biologic therapies, a few
medication cohorts (rituximab, certolizumab,
and tofacitinib) were more often new users.
The findings of this study indicate that there
is a large amount of variability in biologic cost
both within and between condition cohorts,
which may originate from small sample sizes in
some cases. For example, among patients
treated for RA, costs ranged from $18,769 for
treatment with tofacitinib to $30,269 for
adalimumab. Even after excluding the very
small cohort of patients treated with
tofacitinib (n = 5) and rituximab, which has a
unique dosing schedule, results still ranged
from $21,877 to $30,269, which represents a
difference of 38%. The greatest variability was
observed among patients treated for PsO only.
Ustekinumab had the greatest cost ($53,746),
which was 66% more than the cost of
infliximab, 72% more than the cost of
etanercept, and 84% more than the cost of
adalimumab. Another factor that seems to be
associated with increased cost is whether the
patient is new to therapy at index, or
continuing therapy from baseline to follow-up.
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Patients who were new to therapy generally
experienced lower biologic costs, though the
decreased costs may be in part due to lower rates
of persistence and higher rates of
discontinuation without switch or restart. For
patients with PsO only who were new to
therapy, higher costs were seen in the first
year of treatment compared to continuing users
for etanercept and infliximab, most likely
because these medications are recommended
at higher loading doses (up to 12 weeks for
etanercept and up to 6 weeks for infliximab) to
facilitate rapid skin clearance. The rate of
discontinuation without switch or restart for
all patients with RA was lowest among patients
treated with golimumab (4%), infliximab (10%),
and etanercept (11%) indicating that patients
treated with these medications at index were
less likely to have a drug-free period during the
follow-up. While the current study examined
the total cost of biologic treatment in a year, it
did not examine other disease-related costs or
clinical outcomes. Whether discontinuation of
the index biologic led to a worsening of disease
symptoms and greater downstream healthcare
costs warrants further investigation.
Etanercept was the most commonly used
medication in this study and in a prior study [9].
Similar to the prior study, newer biologics had
equivalent or lower costs than etanercept for
RA, PsA, and AS. The current study also
confirms the observation that for biologics
that are indicated for all four inflammatory
diseases (etanercept, adalimumab, and
infliximab), etanercept had the lowest annual
acquisition and administration costs [9].
This study has inherent limitations
associated with observational studies based on
administrative claims. Specifically, while claims
data indicate whether a prescription was filled,
they do not indicate if the medication was used
















































































































































































































































































































































































































































































640 Adv Ther (2016) 33:626–642
patients who were enrolled in a commercial
health plan; results of this analysis may,
therefore, not be generalizable to outcomes in
patient populations with
government-sponsored health insurance (e.g.,
Medicare, Veterans Health Administration
coverage, state Medicaid coverage) or
uninsured populations. Results are also not
generalizable to patients outside the US, as
treatment guidelines and costs vary across
countries. Additionally, claims data lack
clinical data that may impact the
interpretation of the results. Specifically, the
duration of clinical benefit is assumed to be
constant for each of the infused medications,
which could lead to overestimates of persistence
for certain medications. For example, the
estimated duration of clinical benefit for the
last infusion of infliximabmay be too long, since
the label-recommended dosing frequency could
vary from every 8 weeks to every 4 weeks, which
may impart bias by overestimating the clinical
benefit for the last infusion. Similarly, the total
duration of treatment for continuing users is
unknown, leading to potential bias if it differs by
index medication. Important clinical
information such as reasons for treatment
modifications (switch, restart,
discontinuation), and clinical response to the
biologic is unavailable in a claims database.
Claims data also do not contain biometric
information, such as patient weight and thus
weight was not incorporated into dosage
calculations for infused biologics. ICD-9-CM
codes are proxies for actual physician
diagnoses and can be affected by miscoding,
overcoding, and undercoding. All variables may
be subjected, to some extent, to data entry errors
or errors due to rounding (for numerical
variables). These errors, however, are unlikely
to differ across groups or outcomes. Finally, this
study calculated healthcare cost based on the
observed dose and the associated WAC price,
which does not take into account negotiations
between health plans, manufacturer’s rebates, or
other price modifications that could impact the
actual health plan and patient paid amounts.
CONCLUSIONS
The findings from this study indicate that there
is considerable variability in the 1-year cost of
biologic treatment between medications as well
as between indications and in new or
continuing patients. Etanercept was shown to
have lower costs relative to adalimumab and
infliximab across the indications evaluated here
except among patients with PsO only. Of the
medications included in this analysis,
ustekinumab was the most expensive therapy
for PsO. Newer agents may be associated with
lower treatment cost; however, future research
is needed to see if these estimates persist with
expanded use of the more recently approved
biologic.
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